CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study

Stock Information for Cytodyn Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cytodyn Inc

CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer
CytoDyn to Host Investor Webcast
CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026
CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026
CytoDyn to Present at the AACR Annual Meeting 2026
CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer
CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab
CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.